Skip to content

Study · Randomized controlled trial · n = 57 · 1993

5 results

A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.

Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG

Fertility and sterility1 Jul 1993Cited by 180 (Europe PMC)

PMID8513962 (opens in a new tab)DOI10.1016/s0015-0282(16)56039-7 (opens in a new tab)PepBankPUB-08513962
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, goserelin reduced deep dyspareunia more than the oral contraceptive on the linear analog scale.

    In plain wordsIn women with endometriosis, goserelin reduced deep pain during sex more than the oral contraceptive on the linear analog scale.

    Peptide
    Goserelin
    Outcome
    DecreaseDeep dyspareunia
    Study

    n = 57

    Comparator
    Low-dose cyclic oral contraceptive
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    At 6 months of treatment, a significant reduction in deep dyspareunia was observed in both groups, with goserelin superior to the OC at linear analog scale assessment.
    3 context sentences
    Summary · context
    Open-label, randomized trial.
    Summary · context
    Fifty-seven women with moderate or severe pelvic pain and laparoscopically diagnosed endometriosis.
    Summary · context
    Six-month treatment with goserelin depot (n = 29) or a low-dose cyclic OC (n = 28) followed by 6-month follow-up.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, nonmenstrual pain did not differ between goserelin and the oral contraceptive.

    In plain wordsIn women with endometriosis, pain outside menstruation did not differ between goserelin and the oral contraceptive.

    Peptide
    Goserelin
    Outcome
    No significant changeNonmenstrual pain between treatments
    Study

    n = 57

    Comparator
    Low-dose cyclic oral contraceptive
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Nonmenstrual pain was diminished on both scales without differences between treatments.
    3 context sentences
    Summary · context
    Open-label, randomized trial.
    Summary · context
    Fifty-seven women with moderate or severe pelvic pain and laparoscopically diagnosed endometriosis.
    Summary · context
    Six-month treatment with goserelin depot (n = 29) or a low-dose cyclic OC (n = 28) followed by 6-month follow-up.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, symptoms reappeared after treatment without severity differences between goserelin and the oral contraceptive.

    In plain wordsIn women with endometriosis, symptoms returned after treatment with similar severity after goserelin and the oral contraceptive.

    Peptide
    Goserelin
    Outcome
    No significant changeSymptom recurrence severity
    Study

    n = 57

    Comparator
    Low-dose cyclic oral contraceptive
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    At the end of follow-up, symptoms reappeared without differences in severity between the groups.
    3 context sentences
    Summary · context
    Open-label, randomized trial.
    Summary · context
    Fifty-seven women with moderate or severe pelvic pain and laparoscopically diagnosed endometriosis.
    Summary · context
    Six-month treatment with goserelin depot (n = 29) or a low-dose cyclic OC (n = 28) followed by 6-month follow-up.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with endometriosis, nonmenstrual pain diminished on both scales during goserelin treatment.

    In plain wordsIn women with endometriosis, pain outside menstruation decreased on both scales during goserelin treatment.

    Peptide
    Goserelin
    Outcome
    DecreaseNonmenstrual pain change
    Study

    n = 29

    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Nonmenstrual pain was diminished on both scales without differences between treatments.
    3 context sentences
    Summary · context
    Open-label, randomized trial.
    Summary · context
    Fifty-seven women with moderate or severe pelvic pain and laparoscopically diagnosed endometriosis.
    Summary · context
    Six-month treatment with goserelin depot (n = 29) or a low-dose cyclic OC (n = 28) followed by 6-month follow-up.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with endometriosis, deep dyspareunia significantly decreased after six months of goserelin treatment.

    In plain wordsIn women with endometriosis, deep pain during sex decreased compared with baseline after six months of goserelin.

    Peptide
    Goserelin
    Outcome
    DecreaseDeep dyspareunia versus baseline
    Study

    n = 29

    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    At 6 months of treatment, a significant reduction in deep dyspareunia was observed in both groups, with goserelin superior to the OC at linear analog scale assessment.
    2 context sentences
    Summary · context
    Open-label, randomized trial.
    Summary · context
    Six-month treatment with goserelin depot (n = 29) or a low-dose cyclic OC (n = 28) followed by 6-month follow-up.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.